Canaccord lowered the firm’s price target on Merit Medical (MMSI) to $127 from $128 and keeps a Buy rating on the shares. The firm said they reported good Q4 results where they continue to deliver on margin improvement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Strong Growth and Positive Outlook Drive Buy Rating for Merit Medical Systems Despite EPS Challenges
- Merit Medical price target lowered to $117 from $120 at Wells Fargo
- Strong Financial Performance and Strategic Execution Drive Buy Rating for Merit Medical Systems
- Merit Medical Reports Strong 2024 Financial Results
- Merit Medical Systems Reports Strong 2024 Financial Results